Ionis Pharmaceuticals Inc (NASDAQ:IONS) Shorted Shares Increased By 2.29%

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Logo

The stock of Ionis Pharmaceuticals Inc (NASDAQ:IONS) registered an increase of 2.29% in short interest. IONS’s total short interest was 15.47M shares in September as published by FINRA. Its up 2.29% from 15.13M shares, reported previously. With 1.38 million shares average volume, it will take short sellers 11 days to cover their IONS’s short positions.

The stock decreased 1.39% or $0.93 during the last trading session, reaching $65.95. About 1.30M shares traded or 23.70% up from the average. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has risen 50.74% since September 13, 2018 and is uptrending. It has outperformed by 50.74% the S&P500.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company has market cap of $9.27 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. It has a 23.23 P/E ratio. The Company’s drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Ratings Coverage

Among 2 analysts covering Ionis Pharmaceuticals (NASDAQ:IONS), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Ionis Pharmaceuticals has $9600 highest and $55 lowest target. $73’s average target is 10.69% above currents $65.95 stock price. Ionis Pharmaceuticals had 4 analyst reports since March 18, 2019 according to SRatingsIntel. The stock of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has “Neutral” rating given on Monday, March 18 by JP Morgan.

More notable recent Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news were published by: Nasdaq.com which released: “First Week of April 2020 Options Trading For Ionis Pharmaceuticals (IONS) – Nasdaq” on August 23, 2019, also Nasdaq.com with their article: “Notable Monday Option Activity: IONS, X, GD – Nasdaq” published on August 19, 2019, Nasdaq.com published: “Pre-Market Earnings Report for August 7, 2019 : CVS, CNP, NRG, VER, IONS, TEVA, MIDD, LAMR, STWD, NYT, INXN, CPRI – Nasdaq” on August 06, 2019. More interesting news about Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) were released by: Seekingalpha.com and their article: “Ionis Pharmaceuticals, Inc. (IONS) Presents at 17th Annual Morgan Stanley Global Healthcare Conference (Transcript) – Seeking Alpha” published on September 10, 2019 as well as Nasdaq.com‘s news article titled: “IONS Crosses Above Average Analyst Target – Nasdaq” with publication date: June 18, 2019.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.